Shareholding disclosure

Armistice Capital LLC

Declared position

7.62%

Threshold

Crossed upwards

Timeline

Published

28.12.2021

Transaction

16.12.2021

Transfer date

21.12.2021

Voting rights breakdown

Voting rights acquired7.62%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TALCN00035

Beneficial owner

Armistice Capital LLC

Declared address

Armistice Capital LLC, New-York, NY

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Armistice Capital LLC

Addex Therapeutics Ltd28.12.2021TALCN00035

Disclosure summary

Armistice Capital LLC disclosed a holding in Addex Therapeutics Ltd on the acquisition side, published by SIX Exchange Regulation on 28.12.2021, at 7.62% of voting rights. Notice category: Single shareholder.

Disclosed position

7.62%

Voting rights acquired

Voting rights acquired7.62%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Armistice Capital LLC disclosed a holding in Addex Therapeutics Ltd, published on 28.12.2021.

Publication date28.12.2021

Transaction date16.12.2021

Transfer date21.12.2021

Issuing companyAddex Therapeutics Ltd

Beneficial ownerArmistice Capital LLC

Declared addressArmistice Capital LLC, New-York, NY

CategorySingle shareholder

Voting rights acquired7.62%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTALCN00035

Source: SIX Exchange Regulation · Publication date: 28.12.2021

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open